Meeting
2023 ASCO Breakthrough
CRISPincette, and detection of low frequency cancer mutations in ctDNA.
Authors
Jin-Soo Kim
Seoul National University Boramae Medical Center, Seoul, South Korea
Jin-Soo Kim , Yoon-Ho Won , ShinJae Kang , Taegun Park , In Seon Lee , Hyun-jeung Choi , JaeWon Rhee , Mi Young Kim , Junseok W Hur , Sunghyeok Ye
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Gastrointestinal Cancer,Gynecologic Cancer,Head and Neck Cancer,Quality of Care,Genetics/Genomics/Multiomics,Healthcare Equity and Access to Care,Healthtech Innovations,Models of Care and Care Delivery,Population Health,Viral-Mediated Malignancies
Sub Track
Diagnostics
Citation
JCO Global Oncology 9, 2023 (suppl 1; abstr 61)
DOI
10.1200/GO.2023.9.Supplement_1.61
Abstract #
61
Poster Bd #
D6
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Tissue and plasma-based mechanisms of resistance to first-line osimertinib in EGFR-mutant NSCLC: A multi-institutional cohort.
First Author: Zofia Piotrowska
Poster
2021 ASCO Annual Meeting
Targeted ctDNA sequencing analysis reveals concurrent genomic alterations and its impact on TKI and immune checkpoint inhibitor therapy in advanced NSCLC from Asian population.
First Author: Wei Wu
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Novel potential mechanisms of acquired resistance to anti-EGFR monoclonal antibody (mAb) therapy detected in liquid biopsies (LBx) from patients (pts) with advanced colorectal cancer (CRC).
First Author: Christine Megerdichian Parseghian
Poster
2023 ASCO Annual Meeting
Mobocertinib efficacy in patients with NSCLC and EGFR exon 20 insertion mutations (ex20ins) identified by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA).
First Author: Joel W. Neal